· Studies on Covid-19 need to continue to be developed for prevention and management both now and in the future.
· IL-6 and NLR could be a biomarker of the severity of COVID-19 disease
· The differences in serum levels of the pro-inflammatory cytokine IL-6 and the imbalance of inflammatory cells with NLR can be part of the handling procedure for COVID-19.
· The result cut-off> 6.99 pg/mL and Neutrophil Lymphocyte Ratio (NLR) > 4.18 is the potential to be included in laboratory parameters for patient management of COVID-19.